Loading...
•
Dec 31, 2022
Edwards Lifesciences Q4 2022 Earnings Report
Edwards Lifesciences reported a 1 percent increase in Q4 sales, reaching $1.35 billion, and EPS of $0.65.
Key Takeaways
Edwards Lifesciences reported Q4 2022 results, with sales growing 1% to $1.35 billion and adjusted EPS increasing 25% to $0.64. The company highlighted progress on strategic milestones and reiterated its 2023 guidance.
Q4 sales grew 1 percent to $1.35 billion; constant currency sales grew 7 percent
Q4 TAVR sales were flat; constant currency sales grew 5 percent
Q4 EPS of $0.65; adjusted EPS increased 25 percent to $0.64
Reiterated 2023 guidance of 9 to 12 percent constant currency sales growth
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company is reaffirming the sales guidance it provided at the December investor conference for all product groups. Full year 2023 sales are expected to grow 9 to 12 percent to $5.6 to $6.0 billion. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.45 to $2.60.
Positive Outlook
- Expect meaningful growth and progress in 2023
- Expect a gradual improvement in healthcare staffing
- Expect contributions from all major regions
- Enthusiastic about the continued expansion of transcatheter-based therapies
- Well positioned for long-term success
Revenue & Expenses
Visualization of income flow from segment revenue to net income